Analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to post sales of $63.15 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $62.00 million and the highest is $64.30 million. Amphastar Pharmaceuticals reported sales of $56.67 million during the same quarter last year, which would suggest a positive year over year growth rate of 11.4%. The firm is scheduled to announce its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Amphastar Pharmaceuticals will report full year sales of $290.83 million for the current year, with estimates ranging from $277.00 million to $304.00 million. For the next financial year, analysts forecast that the firm will report sales of $413.64 million per share, with estimates ranging from $367.50 million to $468.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Monday, March 12th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. The firm had revenue of $60.40 million for the quarter, compared to analysts’ expectations of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 EPS.
AMPH has been the topic of a number of recent analyst reports. BidaskClub raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a research report on Tuesday, January 23rd. BMO Capital Markets reaffirmed a “market perform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Piper Jaffray reaffirmed a “buy” rating and issued a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Finally, Wells Fargo reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.33.
Shares of AMPH stock opened at $19.18 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. The stock has a market cap of $878.81, a PE ratio of 50.47, a PEG ratio of 1.35 and a beta of 1.41. Amphastar Pharmaceuticals has a twelve month low of $13.15 and a twelve month high of $20.45.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 16,598 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $19.90, for a total transaction of $330,300.20. Following the sale, the director now directly owns 45,442 shares in the company, valued at $904,295.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 19,801 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $20.10, for a total transaction of $398,000.10. The disclosure for this sale can be found here. Insiders sold 84,387 shares of company stock worth $1,659,763 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the business. Paloma Partners Management Co purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $197,000. Stone Ridge Asset Management LLC purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $214,000. Renaissance Technologies LLC purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $227,000. Driehaus Capital Management LLC purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $229,000. Finally, Teacher Retirement System of Texas purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $242,000. Institutional investors own 44.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 Million” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/17/amphastar-pharmaceuticals-inc-amph-expected-to-post-quarterly-sales-of-63-15-million-2.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.